Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis

Blood

Volumn 109, Issue 2, 2007, Pages 560-565

  Arbiser, Jack L ^a   Kau, Tweeny ^b   Konar, Martha ^c   Narra, Krishna ^d   Ramchandran, Ramani ^c   Summers, Scott A ^d   Vlahos, Chris J ^e   Ye, Keqiang ^a,f   Perry, Betsy N ^a   Matter, William ^e   Fischl, Anthony ^e   Cook, James ^e   Silver, Pamela A ^b   Bain, Jenny ^g   Cohen, Philip ^g   Whitmire, David ^h   Furness, Scott ^h   Govindarajan, Baskaran ^a   Bowen, J Phillip ⁱ  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f MEDICAL RESEARCH COUNCIL   (United Kingdom)

^g UNIVERSITY OF DUNDEE   (United Kingdom)

^h UNIVERSITY OF GEORGIA   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOLENOPSIN A; TRANSCRIPTION FACTOR FKHR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG ISOLATION; EMBRYO; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; FERTILIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 33846231294     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-06-029934     Document Type: Article

References (41)

1. Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt PK. The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci U S A. 1998;95:14950-14955.
2. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991;254:274-277.
3. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 1997;385:544-548.
4. Watton SJ, Downward J. Akt/PKB localisation and 3′ phosphoinositide generation at sites of epithelial cell-matrix and cell-cell interaction. Curr Biol. 1999;9:433-436.
5. Klafter R, Arbiser JL. Regulation of angiogenesis and tumorigenesis by signal transduction cascades: lessons from benign and malignant endothelial tumors. J Investig Dermatol Symp Proc. 2000;5:79-82.
6. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 1997;17:1595-1606.
7. Summers SA, Lipfert L, Birnbaum MJ. Polyoma middle T antigen activates the Ser/Thr kinase Akt in a PI3- kinase-dependent manner. Biochem Biophys Res Commun. 1998;246:76-81.
8. Songyang Z, Baltimore D, Cantley LC, Kaplan DR, Franke TF. Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci U S A. 1997;94:11345-11350.
9. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem. 1998;273:30336-30343.
10. Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J. 1998;335:1-13.
11. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318-1321.
12. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappa B and tumor progression. Cancer Res. 2002;62:7335-7342.
13. Parrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem. 1997;272:154-161.
14. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003;2:1093-1103.
15. Gills JJ, Holbeck S, Hollinshead M, Hewitt SM, Kozikowski AP, Dennis PA. Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol Cancer Ther. 2006;5:713-722.
16. Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A. 1997;94:861-866.
17. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med. 1998;4:376-383.
18. Bai X, Cerimele F, Ushio-Fukai M, et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem. 2003;278:35501-35507.
19. Arbiser JL, Panigrathy D, Klauber N, et al. The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. J Am Acad Dermatol. 1999;40:925-929.
20. Moriyama Y, Doanhuyn D, Monneret C, Khuonghuu Q. Piperidine alkaloids 4: new synthesis of (+/-) solenopsin-A via heterocyclization-aminomercuration. Tetrahedron Lett. 1977;18:825-828.
21. Leclercq S, Thirionet I, Broeders F, Daloze D, Vandermeer R, Braekman JC. Absolute-configuration of the solenopsins, venom alkaloids of the fire ants. Tetrahedron. 1994;50:8465-8478.
22. Comins DL, Brooks CA, Ingalls CL. Reduction of N-acyl-2,3-dihydro-4- pyridones to N-acyl-4-piperidones using zinc/acetic acid. J Org Chem. 2001;66:2181-2182.
23. Beak P, Lee WK. Alpha-lithioamine synthetic equivalents from N-Boc piperidine. Abstr Pap Am Chem Soc. 1990;200:248-ORGN.
24. Wilkinson TJ, Stehle NW, Beak P. Enantioselective syntheses of 2-alkyl- and 2,6-dialkylpiperidine alkaloids: preparations of the hydrochlorides of (-)-coniine, (-)-solenopsin A, and (-)-dihydropinidine. Org Lett. 2000;2:155-158.
25. Kau TR, Schroeder F, Wojciechowski CL, et al. Phosphoinositol-3 kinase/akt signaling: a chemical genetic screen for inhibitors of FOXO1a nuclear export. Clin Can Res. 2003;9:6138S-6139S.
26. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95-105.
27. Meier TI, Cook JA, Thomas JE, et al. Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms. Protein Expr Purif. 2004;35:218-224.
28. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic-development of the zebrafish. Dev Dyn. 1995;203:253-310.
29. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol. 2002;248:307-318.
30. Wang LP, Summers SA. Measuring insulin-stimulated phosphatidyl-inositol 3-kinase activity. Methods Mol Med. 2003;83:127-136.
31. Chen H, Kovar J, Sissons S, et al. A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Anal Biochem. 2005;338:136-142.
32. Bain J, McLauchlan H, Elliot M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J. 2003;371:199-204.
33. LaMontagne KR Jr, Moses MA, Wiederschain D, et al. Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am J Pathol. 2000;157:1937-1945.
34. Chan J, Bayliss PE, Wood JM, Roberts TM. Dissection of angiogenic signaling in zebrafish using a chemical genetic approach. Cancer Cell. 2002;1:257-267.
35. deShazo RD, Butcher BT, Banks WA. Reactions to the stings of the imported fire ant. N Engl J Med. 1990;323:462-466.
36. deShazo RD, Williams DF, Moak ES. Fire ant attacks on residents in health care facilities: a report of two cases. Ann Intern Med. 1999;131:424-429.
37. Verma NK, Dey CS. The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro. Diabetologia. 2006;49:1656-1660.
38. Knowling M, Blackstein M, Tozer R, et al. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs. 2006;24:435-439.
39. Ernst DS, Eisenhauer E, Wainman N, et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs. 2005;23:569-575.
40. Burg MA, Pasqualini R, Arap W, Ruoslahti E, Stallcup WB. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res. 1999;59:2869-2874.
41. Ran S, Gao BN, Duffy S, Watkins L, Rote N, Thorpe PE. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res. 1998;58:4646-4653.